Five Prime Therapeutics: Morgan Stanley Global Healthcare Conference (Five Prime Therap, Morgan Stanley Global Healthcare Conference 2016) - Sep 21, 2016 - “The preliminary objective response rate (as of April 18, 2016) was 39%, with a disease control rate of 100% (evaluable patients, 10 and 15 mg/kg GSK3052230, confirmed per mRECIST 1.1)”
P1 data • Oncology
|